Duchenne News Tags: Dyne Therapeutics

May 20, 2024
On Monday, May 20, Dyne Therapeutics announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its ongoing Phase...
March 23, 2023
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne
November 7, 2022
Dyne Therapeutics receives FDA Fast Track designation for DYNE-251 for treatment of Duchenne
August 11, 2022
On August 10, 2022, Dyne Therapeutics announced the publication of Duchenne muscular dystrophy preclinical data: Enhanced Exon Skipping and Prolonged Dystrophin Restoration Achieved by TfR1-Targeted Delivery of Antisense Oligonucleotide Using...
July 5, 2022
On July 5, 2022, Dyne Therapeutics announced that the U.S. Food and Drug Administration lifted the hold and cleared their Investigational New Drug application for DYNE-251.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open